Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund). Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.

Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry.

Chris is currently a director of; Azura Ophthalmics, Certa Therapeutics, EBR Systems, Global Kinetics Corporation, OccuRx, Osprey Medical, PolyActiva and Que Oncology. He is also an advisory board member for The WILD Program.

Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne. Chris is a member of the Australian Institute of Company Directors and of AusBiotech.